Regeneus stem cell therapy reaches Melbourne
Regeneus (ASX:RGS) has announced that its stem cell therapy HiQCell is now available in Melbourne for the first time.
The company has established a new cell-processing laboratory at Linley Clinic Private Hospital in collaboration with sports and exercise physician Dr Philip Bloom at Bounce Health Group.
HiQCell is an autologous point-of-care therapy for musculoskeletal conditions including osteoarthritis. It is designed to reduce inflammation and repair damaged tissue.
The therapy is derived from a patient’s adipose (fat) tissue, as extracted by a treating medico. Regeneus staff then use the tissue to prepare a cell therapy in-clinic.
The therapy has to date been used in over 800 joints from more than 350 people in New South Wales and Queensland, but this launch marks a debut in Victoria.
Regeneus is also developing Cryoshot, an allogeneic cell therapy for joint conditions in animals, and has a human product based on the same technology in preclinical trials.
The company recently concluded a $10.5 million IPO, the first Australian biotech float since 2011.
Regeneus (ASX:RGS) shares grew 4% on Wednesday to $0.255 after the debut was announced.
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
Newborns have elevated levels of an Alzheimer's biomarker
What do the brains of newborns and patients with Alzheimer's disease have in common? Both...
